Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Nonmalignant Clonal Hematopoiesis

Laura W. Dillon¹, Jack Ghannam², Chidera Nosiri¹, Gege Gui¹, Meghali Goswami¹, Katherine R. Calvo², Katherine E. Lindblad¹, Karolyn A. Oetjen¹, Matthew D. Wilkerson³,⁴,⁵, Anthony R. Soltis³,⁴, Gauthaman Sukumar⁴,⁶, Clifton L. Dalgard⁵,⁶, Julie Thompson¹, Janet Valdez¹, Christin B. DeStefano¹, Catherine Lai¹, Adam Sciambi⁷, Robert Durruthy-Durruthy⁷, Aaron Llanso⁷, Saurabh Guati⁷, Shu Wang⁷, Aik Ooi⁷, Pradeep K. Dagur⁸, J. Philip McCoy⁸, Patrick Burr⁹, Yuesheng Li⁹, and Christopher S. Hourigan¹

ABSTRACT

Genetic mutations associated with acute myeloid leukemia (AML) also occur in age-related clonal hematopoiesis, often in the same individual. This makes confident assignment of detected variants to malignancy challenging. The issue is particularly crucial for AML posttreatment measurable residual disease monitoring, where results can be discordant between genetic sequencing and flow cytometry. We show here that it is possible to distinguish AML from clonal hematopoiesis and to resolve the immunophenotypic identity of clonal architecture. To achieve this, we first design patient-specific DNA probes based on patient’s whole-genome sequencing and then use them for patient-personalized single-cell DNA sequencing with simultaneous single-cell antibody-oligonucleotide sequencing. Examples illustrate AML arising from DNMT3A- and TET2-mutated clones as well as independently. The ability to personalize single-cell proteogenomic assessment for individual patients based on leukemia-specific genomic features has implications for ongoing AML precision medicine efforts.

SIGNIFICANCE: This study offers a proof of principle of patient-personalized customized single-cell proteogenomics in AML including whole-genome sequencing–defined structural variants, currently unmeasurable by commercial “off-the-shelf” panels. This approach allows for the definition of genetic and immunophenotype features for an individual patient that would be best suited for measurable residual disease tracking.

¹Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. ²Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland. ³Precision Medicine Initiative for Military Medical Research and Education, Uniformed Services University of the Health Sciences, Bethesda, Maryland. ⁴Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, Maryland. ⁵Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, Maryland. ⁶The American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, Maryland. ⁷Mission Bio, Inc., South San Francisco, California. ⁸Flow Cytometry Core, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. ⁹DNA Sequencing and Genomics Core, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Note: Supplementary data for this article are available at Blood Cancer Discovery Online (https://bloodcancerdiscov.aacrjournals.org/).

L.W. Dillon, J. Ghannam, and C. Nosiri contributed equally to this article.

Corresponding Author: Christopher S. Hourigan, Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

doi: 10.1158/2643-3230.BCD-21-0046
©2021 American Association for Cancer Research

Downloaded from https://bloodcancerdiscov.aacrjournals.org/ by guest on July 26, 2021. Copyright 2021 American Association for Cancer Research.
INTRODUCTION

Age-related clonal hematopoiesis (also known as clonal hematopoiesis of indeterminate potential) is seen in those without hematologic malignancy and with a somatic mutation detectable in a clonal population of mature blood cells (1-3). These mutations, most commonly in epigenetic regulators DNMT3A and TET2, typically are found in older individuals and appear to be associated with an increased risk for death, predominately from inflammation-associated vascular events (4). These mutations are also common in patients with acute myeloid leukemia (AML; ref. 5) and can make genomic measurement of residual disease challenging (6, 7). Single-cell DNA sequencing (scDNA-seq) for AML has recently been described (8, 9) but has yet to be used for the detection of novel chromosomal fusions that are the key, and often only, defining feature for multiple subtypes of this disease. We performed deep laboratory interrogation of samples, using whole-genome and targeted error-corrected sequencing, scDNA-seq with antibody–oligonucleotide conjugates, and multiparameter flow cytometry, from three adult patients with relapsed AML who harbored mutations detected potentially attributable to either leukemia or clonal hematopoiesis.

RESULTS

Patient 1 was a 74-year-old man with a second relapse of AML. Comorbidities included type 2 diabetes with neuropathy, retinopathy and peripheral vascular disease, hypertension, hyperlipidemia, coronary arterial disease, congestive heart failure, active tobacco use with chronic obstructive pulmonary disease, and obstructive sleep apnea. Prior chemotherapy included clofarabine and cytarabine. Clinical flow cytometry identified a 1% CD34-positive population of abnormal blasts in blood. Blood marrow metaphase cytogenetics revealed a 47,XY karyotype with inversion of chromosome 16 and trisomy of chromosome 8 in four metaphases. A mutation in DNMT3A was noted by clinical DNA sequencing (DNA-seq), with additional mutations in DNMT3A and TET2 also noted in error-corrected research DNA-seq (Table 1).

Patient 2 was a 63-year-old woman with a second relapse of AML. No vascular, diabetic, or other comorbidities were noted. Prior chemotherapy had included three rounds of intensive chemotherapy (idarubicin and cytarabine followed by cytarabine consolidation, and then salvage therapy with cytarabine, etoposide, and mitoxantrone). Clinical flow cytometry identified a 9% CD117-positive population of abnormal blasts in blood. Blood marrow metaphase cytogenetics revealed a 47,XY karyotype with inversion of chromosome 16 and trisomy of chromosome 8 in four metaphases. A mutation in DNMT3A was noted by clinical DNA sequencing (DNA-seq), with additional mutations in DNMT3A and TET2 also noted in error-corrected research DNA-seq (Table 1).

Patient 3 was a 71-year-old man with a first relapse of AML. Concurrent comorbidities included hypertension and hyperlipidemia. He had previously received intensive chemotherapy with idarubicin and cytarabine induction followed by cytarabine consolidation. Clinical flow cytometry identified a 4.4% CD117-positive population of abnormal blasts in BM. Clinical DNA-seq noted mutations in both DNMT3A and TET2, and research sequencing confirmed these and also identified mutations in GATA2 and CEBPA (Table 1).

In all three patients, the relationship between mutations discovered by targeted DNA-seq, leukemia-associated chromosomal abnormalities, and aberrant immunophenotype was unclear based on clinical evaluation.

In the first two patients, with known chromosomal structural abnormality from clinical metaphase cytogenetics, whole-genome sequencing (WGS) was performed for exact DNA breakpoint determination using BM aspirate sorted for either CD34 or CD117 positivity based on clinical immunophenotype (Fig. 1; Supplementary Fig. S1). Patient-specific primers for scDNA-seq (Mission Bio, Inc.) were then designed to detect these breakpoints and also mutations identified by clinical and research-targeted DNA-seq (Supplementary Table S1). Both chromosomal breakpoints and mutations found by bulk targeted DNA-seq were detected by scDNA-seq (Supplementary Fig. S2).

Profiling cell-surface protein expression using antibody-oligo conjugates with scDNA-seq has recently been described (10). The use of antibody–oligo conjugates in these scDNA-seq experiments could approximate the cell-surface immunophenotypic expression distributions as benchmarked by multiparameter flow cytometry (Supplementary Fig. S3). This ability to pair cell-surface immunophenotype with scDNA-seq genotyping for both chromosomal aberrations and sequence mutations allowed us to fully resolve the relationship between clonal hematopoiesis and AML in all three patients.

Five independent genetically defined clones were found in peripheral blood mononuclear cells (PBMC) of patient 1 (Fig. 2; Supplementary Fig. S4A). The pathognomonic inversion 16 breakpoint was detected in 13% of cells examined and was mutually exclusive from clones containing DNMT3A and TET2 mutations. Trisomy of chromosome 8 was found in cells containing inversion 16 but not in other clones. Although clinical flow cytometry described a 1% abnormal blast population positive for CD13, CD34, and CD117, this particular immunophenotype represented only half of the cells genotyped as containing inversion 16 and trisomy 8. This leukemic genotype was also found in cells with an immunophenotype consistent with more mature myeloid cell types (CD11b, CD33, and CD123 positive) but notably not in T (CD3) or B (CD19) lymphocytes. In contrast, the three subclones each containing one mutation in either DNMT3A or TET2 did not have any restriction to myeloid or lymphoid lineages.

Unlike this first case, patients 2 and 3 both had AML that likely arose from a preceding clonal hematopoiesis cell population. ScDNA-seq of BM mononuclear cells (BMMC) from patient 2 demonstrated that 20% of cells contained the leukemia-defining features of t(6;14) translocation and mutated U2AF1, in addition to the DNMT3A and CUX1 mutations that were within but not specific to this clone (Fig. 3A; Supplementary Fig. S4B). The NPM1 mutation was incompletely genotyped (see Methods). This malignant clone had a diverse range of immunophenotypes including both CD117-positive and CD117-negative populations. Cells containing mutations in DNMT3A and CUX1 but not the t(6;14) translocation and U2AF1 mutation represented just 5% of cells.
Table 1. Patient genetic characteristics

<table>
<thead>
<tr>
<th>P</th>
<th>Age, y/sex</th>
<th>Cytogenetics</th>
<th>Gene</th>
<th>HGVSc/ HGVSp</th>
<th>Chr</th>
<th>Position</th>
<th>Ref</th>
<th>Alt</th>
<th>Consequence</th>
<th>VAF</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>74/M</td>
<td>+8, inv(16)q12(p13.1), del(20)q11.2q13.3</td>
<td>DNMT3A*</td>
<td>NM_022552.4:c.811delG NP_072046.2: p.Asp271ThrfsTer45</td>
<td>2</td>
<td>25470949</td>
<td>TC</td>
<td>T</td>
<td>Frameshift</td>
<td>0.22</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>DNMT3A</td>
<td>NM_022552.4:c.2408+5G&gt;A NP_0011127208.2:c.5037C&gt;A NP_0011120680.1;p.Tyr1679Ter</td>
<td>2</td>
<td>25461994</td>
<td>C</td>
<td>T</td>
<td>Splicing</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TET2</td>
<td>NM_0011120680.1;p.Tyr1679Ter</td>
<td>4</td>
<td>106196704</td>
<td>C</td>
<td>A</td>
<td>Nonsense</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MYH11-CBFb</td>
<td>N/A</td>
<td>16</td>
<td>15815094</td>
<td>N/A</td>
<td>N/A</td>
<td>Fusion gene</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>16</td>
<td>67131781</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>63/F</td>
<td>t(6;14)(q25;q22)</td>
<td>CUX1*</td>
<td>NM_181552.3:c.2195del NP_085350.2: p.Pro732HisfsTer33</td>
<td>7</td>
<td>101844770</td>
<td>AC</td>
<td>A</td>
<td>Frameshift</td>
<td>0.07</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>DNMT3A</td>
<td>NM_022552.4:c.2645G&gt;A NP_001127208.2:c.5037C&gt;A NP_0011120680.1;p.Tyr1679Ter</td>
<td>2</td>
<td>25457242</td>
<td>C</td>
<td>T</td>
<td>Missense</td>
<td>0.07</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NPM1*</td>
<td>NM_0011127208.2:c.860_863dup</td>
<td>5</td>
<td>170837543</td>
<td>C</td>
<td>TCTG</td>
<td>Frameshift</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>U2AF1*</td>
<td>NM_006758.2:c.101C&gt;A NP_006749.1:p.Ser34Tyr</td>
<td>21</td>
<td>44524456</td>
<td>G</td>
<td>T</td>
<td>Missense</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TIAM2-PPP2R5E</td>
<td>N/A</td>
<td>6</td>
<td>155159590</td>
<td>N/A</td>
<td>N/A</td>
<td>Fusion gene</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>14</td>
<td>63959402</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>71/M</td>
<td>Normal</td>
<td>CEBPA</td>
<td>NM_004364.4:c.949_950insGTC NP_004355.2: p.His24AlafsTer84</td>
<td>19</td>
<td>33792371</td>
<td>A</td>
<td>AGAC</td>
<td>Inframe insertion</td>
<td>0.08</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CEBPA</td>
<td>NM_004364.4:c.68dup NP_004355.2: p.His24AlafsTer84</td>
<td>19</td>
<td>33793252</td>
<td>C</td>
<td>CG</td>
<td>Frameshift</td>
<td>0.07</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>DNMT3A*</td>
<td>NM_022552.4:c.1979A&gt;G NP_072046.2:p.Tyr660Cys</td>
<td>2</td>
<td>25464534</td>
<td>T</td>
<td>C</td>
<td>Missense</td>
<td>0.20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GATA2</td>
<td>NM_032638.4:c.1085G&gt;A NP_116027.2:p.Arg362Gln</td>
<td>3</td>
<td>128200720</td>
<td>T</td>
<td>C</td>
<td>Missense</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TET2*</td>
<td>NM_0011127208.2:c.3954+1G&gt;T N/A</td>
<td>4</td>
<td>106180927</td>
<td>G</td>
<td>T</td>
<td>Splicing</td>
<td>0.17</td>
</tr>
</tbody>
</table>

Abbreviations: Alt, alternate; Chr, chromosome; F, female; HGVSc, human genome variation society cDNA nomenclature; HGVSp, HGVS protein nomenclature; M, male; N/A, not applicable; P, patient; Ref, reference; VAF, variant allele frequency; y, year.

*Identified by clinical and research sequencing.

ScDNA-seq of BMMCs from patient 3 identified a clone representing 16% of cells that contained $DNMT3A$, $TET2$, $CEBPA$, and $GATA2$ mutations and was markedly enriched for CD117 cell-surface protein expression (Fig. 3B; Supplementary Fig. S4C). $CEBPA$ was incompletely genotyped but found only within cells with mutated $GATA2$ (see Methods). Cells containing mutations in $DNMT3A$ and $TET2$ but not $GATA2$ or $CEBPA$, presumably representing the founder population of nonmalignant clonal hematopoiesis, represented 26% of all BM cells sequenced and had a diverse spectrum of immunophenotypes ranging across both myeloid and lymphoid lineages.

The individual patient clonal structures determined by scDNA-seq were confirmed by sorting on the predominant cell-surface protein followed by WGS. For patient 1, CD34-positive BM cells had enrichment of trisomy of chromosome 8 and inversion 16 relative to bulk BM sequencing, with $DNMT3A$ and $TET2$ mutations not detected. For patients 2 and 3, WGS of CD117-positive cells confirmed the enrichment of all mutations, and, as predicted, unlike patient 1, the $DNMT3A$ and $TET2$ mutations remained detectable (Supplementary Table S2).

**DISCUSSION**

This is the first (to our knowledge) description of WGS-informed, patient-personalized scDNA-seq to accurately distinguish leukemic cells from clonal hematopoiesis. This is also the first direct comparison of antibody-oligonucleotide and such scDNA-seq with concurrent multiparameter flow cytometry.
The ability to determine the optimum combinations of immunophenotypic markers necessary to identify malignant subclones may have utility in flow cytometric approaches for measurement of residual AML, which currently underrepresent total genetically defined leukemic burden. Although targeted DNA-seq cannot determine if mutations associated with clonal hematopoiesis are also represented within the malignant clone, detection of pathognomonic fusion genes by single-cell DNA and antibody–oligonucleotide sequencing can resolve, and determine the immunophenotype of, the relevant leukemic clonal architecture, allowing comprehensive and personalized assessment of AML. This integrated multimodal approach has implications for precision medicine in AML and other diseases.

**METHODS**

**Clinical Samples**

BM aspirate and peripheral blood (PB) samples were collected from patients with relapsed or refractory AML after receipt of written informed consent on a National Heart, Lung, and Blood Institute (NHLBI) Institutional Review Board–approved protocol in accordance with the Declaration of Helsinki. BMMCs were purified from BM aspirate and PBMCs from PB using density centrifugation, cryopreserved, and stored in liquid nitrogen. Genomic DNA (gDNA) was isolated either from fresh heparinized BM aspirate using the QIAamp DNA Blood Midi Kit or from thawed PBMCs or BMMCs using the QIAamp DNA Micro Kit (QIAGEN).

**Targeted DNA-seq**

Mutations were identified in each patient by error-corrected DNA-seq of 50 ng of gDNA using a panel covering 75 genes commonly mutated in myeloid malignancies (Myeloid VariantPlex, ArcherDx). The resulting libraries were subjected to paired-end 150-bp sequencing on a MiSeq (Illumina). Raw sequencing FASTQ files were analyzed using the Archer Analysis software version 6.0.2.3. AML-associated variants (Table 1), with a minimum variant allele frequency of 0.01, were identified using information regarding unique molecular identifiers (UMI) read families, background error rate models, unique start sites, strand-specific priming, homopolymer runs, and predicted variant consequence.

**WGS**

WGS was performed on all patients to determine the DNA breakpoint locations of known cytogenetic rearrangements (patients 1 and 2) and to confirm immunophenotype-genotype relationships. gDNA isolated from buccal swabs, bulk BM aspirate, and microbead (Miltenyi Biotec) positively enriched CD34- or CD117-positive cells from BMMCs were used for WGS library preparation using the TruSeq DNA PCR-Free Kit with ligation of IDT for Illumina TruSeq DNA UD Indexes. Libraries were clustered in a single library per lane topography (with five lanes per AML library and one lane per germline library) on a cBot2 (Illumina) before sequencing on a HiSeq X platform (Illumina) to generate paired-end 150-bp reads. WGS raw data were converted from BCL to FASTQ format using Illumina’s bcl2fastq v2.20. Samples were processed by the HAS2.2 (Illumina) resequencing analysis workflow. Reads were aligned to the hg38 reference genome plus decoy sequences using isaac (version Isaac-04.17.06.15). Then, matched tumor and normal results were analyzed by Illumina’s tumor normal workflow, which included somatic variant detection by strelka2 (version 2.80), somatic structural variant detection by manta (version 1.1.1), and somatic copy-number detection by canvas (version 1.28.0.272). Breakpoint locations for fusion partners were chosen for further analysis (Table 1; Fig. 1; Supplementary Fig. S1).

**Single-Cell DNA and Protein Sequencing**

ScDNA-seq with antibody–oligonucleotide staining was performed using the Mission Bio Tapestry scDNA-seq V2 platform as per the manufacturer’s instructions. In short, custom scDNA-seq panels targeting the patient-specific mutations and chromosomal structural abnormalities (Table I; Supplementary Table S1) and oligonucleotide-conjugated antibodies (AOC) targeting cell-surface proteins of interest (Supplementary Table S3) were designed and manufactured by Mission Bio, Inc. Approximately 15,000 thawed BMMCs or PBMCs were stained for 30 minutes at room temperature with the AOC pool, followed by four rounds of washing with Dulbecco’s phosphate-buffered saline (DPBS) containing 7% FBS. Stained cells were resuspended...
in cell buffer and subjected to microfluidic encapsulation, lysis, and cell barcoding on the Tapestry instrument. Amplification of the targeted DNA regions and antibody-oligonucleotide tags was performed by incubating the barcoded DNA emulsions in a thermocycler as follows: 98°C for 3 minutes; 10 cycles of 95°C for 20 seconds, 62°C for 20 seconds, 48°C for 3 minutes; 10 cycles (protein library) or 20 cycles (DNA library) of 95°C for 20 seconds, 72°C for 45 seconds; and 72°C for 2 minutes. Final libraries were purified with 0.69X (DNA) or 0.9X (protein) SPRISelect reagent. Libraries were pooled and subjected to paired-end 150-bp sequencing on a Novaseq 6000 (Illumina).

Raw FASTQ files were analyzed using the Tapestry pipeline (MissionBio) and custom python scripts. An average of 1,797 cells were sequenced per patient (Supplementary Table S4). Single-nucleotide variants and indels identified via GATK were filtered for quality score, read depth, and minimum frequency. In order to confidently delineate clonal structure, only variants genotyped in a high proportion of cells were considered for subclone analysis. Multiple variants exhibited characteristics of incomplete genotyping for various technical reasons. The amplicon covering

---

**Figure 2.** Development of leukemia independent from clonal hematopoiesis. A, Clonal architecture as determined by scDNA and antibody–oligonucleotide sequencing in patient 1 shows the leukemic (AML, red line) clone developed separately from three clonal hematopoiesis (CHIP, gray lines) clones. Left: Genomic variants and structural changes identified. Center: Immunophenotype as a percentage of each subclone. Right: Cell-surface protein expression for each subclone. B, For patient 1, cells clustered by cell-surface protein expression. UMAP shown colored by immunophenotype (top left) and genotype, with all subclones (bottom left), the leukemic subclone (top right), and one clonal hematopoiesis subclone (bottom right) depicted. VAF, variant allele frequency.
the CEBPA c.68dup failed amplification in all patients. The NPM1 c.860_863dup variant is located just downstream from a homopolymer run region, which presented difficulty on the Illumina sequencer, resulting in poor quality reads and subsequent read trimming. In the custom panel used for patients 2 and 3 (CO-86), the reverse primer was situated such that the insertion site was not covered, resulting in allelic dropout across many cells. This technical issue was resolved in the newer custom panel used for patient 1 (CO-101), drastically improving coverage. The CEBPA c.949_950insGTC mutation is also located within a difficult-to-sequence region, which also resulted in poor read quality and subsequent allelic dropout across cells.

Next, UMAP dimension reduction and clustering were applied to identify subclone populations. The presence of inversions or translocations in those subclones was noted by counting amplicons spanning the splice junctions. Copy-number variation was calculated by identifying subclones with wild-type (WT), heterozygous (HET), present (+), or absent (−) features. Center: Immunophenotype as a percentage of each subclone. Right: Cell-surface protein expression for each subclone. VAF, variant allele frequency.

**Figure 3.** Sequential development of leukemia from clonal hematopoiesis. Clonal architecture as determined by scDNA and antibody–oligonucleotide sequencing in patient 2 (A) and patient 3 (B) shows the leukemic (AML, red line) clone developed from clonal hematopoiesis (CHIP, gray line). Left: Genomic subclones with wild-type (WT), heterozygous (HET), present (+), or absent (−) features. Center: Immunophenotype as a percentage of each subclone. Right: Cell-surface protein expression for each subclone. VAF, variant allele frequency.

Flow Cytometry

Thawed PBMCs or BMMCs were resuspended in Cell Staining Buffer (BioLegend) and blocked with Human TruStain FcX (Fc Receptor Blocking Solution; BioLegend) for 10 minutes. Cells were stained with a 1:100 dilution of Zombie UV Fixable Viability dye (BioLegend) for 10 minutes and then incubated with 5 µL of each antibody listed in Supplementary Table S5 for 20 minutes. All steps were performed at ambient temperatures. At least 100,000 events were acquired with a BD FACSymphony; data were analyzed with FlowJo Software version 10 (BD).

Data Availability

FASTQ files from scDNA and antibody sequencing and targeted DNA-seq are available in the NCBI SRA (PRJNA718560). FCS files for flow cytometry are available in FlowRepository (FR-FCM-Z3LT).

Authors’ Disclosures

M.D. Wilkerson reports grants from National Heart, Lung, and Blood Institute and Defense Health Agency during the conduct of the study. C.L. Dalgard report grants from National Heart, Lung, and Blood Institute and Defense Health Agency during the conduct of the study. A. Sciambi reports other support from Mission Bio, Inc. outside the submitted work, as well as a patent for US App. No. 16/839,055 pending. A. Llanso reports other support from Mission Bio, Inc. during the conduct of the study; other support from Mission Bio, Inc. outside the submitted work; and a patent for US App. No. 16/839,055 pending. S. Gulati reports personal fees from Mission Bio, Inc. during the conduct of the study, as well as personal fees from Mission Bio, Inc. outside the submitted work. S. Wang reports other support from Mission Bio, Inc. outside the submitted work; and a patent for US App. No. 16/839,055 pending. C.S. Hourigan reports other support from Merck and Sellas outside the submitted work; and a patent for US App. No. 16/839,055 pending. A. Llanso reports other support from Mission Bio, Inc. outside the submitted work. S. Wang reports other support from Mission Bio, Inc. during the conduct of the study. A. Ooi reports grants from National Cancer Institute during the conduct of the study; other support from Mission Bio, Inc. outside the submitted work; and a patent for US App. No. 16/839,055 pending. C.S. Hourigan reports other support from Merck and Sellas outside the submitted work. No disclosures were reported by the other authors.

Disclaimer

The opinions and assertions expressed herein are those of the author(s) and do not necessarily reflect the official policy or position of the Uniformed Services University or the Department of Defense.
the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., or the National Institutes of Health.

**Authors’ Contributions**

L.W. Dillon: Conceptualization, data curation, formal analysis, investigation, visualization, methodology, writing—original draft, writing—review and editing. J. Thompson: Conceptualization, data curation, formal analysis, writing—review and editing. C. Nosiri: Conceptualization, data curation, formal analysis, writing—review and editing. G. Gui: Data curation, formal analysis, visualization, writing—review and editing. A.R. Soltis: Data curation, writing—review and editing. R. Durruthy-Durruthy: Conceptualization, data curation, formal analysis, writing—review and editing. M. Wilkerson: Data curation, writing—review and editing. K.A. Oetjen: Data curation, writing—review and editing. J. Valdez: Data curation, writing—review and editing. C.L. Dalgard: Data curation, writing—review and editing. G. Sukumar: Conceptualization, data curation, formal analysis, writing—review and editing. Y. Li: Resources, writing—review and editing. A. Sciambi: Formal analysis, visualization, writing—review and editing. C.B. Destefano: Data curation, writing—review and editing. J. Valdez: Data curation, writing—review and editing. J. Thompson: Data curation, writing—review and editing. J. Ghannam: Conceptualization, data curation, formal analysis, writing—review and editing. C. Nosiri: Conceptualization, data curation, formal analysis, writing—review and editing. K.R. Calvo: Data curation, formal analysis, writing—review and editing. G. Gui: Data curation, writing—review and editing. M. Wilkerson: Data curation, writing—review and editing. A. Llanso: Resources, writing—review and editing. S. Gulati: Resources, writing—review and editing. A. Ooi: Resources, writing—review and editing. S. Wang: Resources, writing—review and editing. C.S. Hourigan: Conceptualization, resources, formal analysis, supervision, funding acquisition, investigation, methodology, writing—original draft, project administration, writing—review and editing.

**Acknowledgments**

This work was supported by the Intramural Research Program of the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) and by the Department of Defense award HU0001-18-2-0038 to C.L. Dalgard.

This work utilized the NHLBI Flow Cytometry Core, the NHLBI Sequencing and Genomics Core, and the computational resources of the NIH HPC Biowulf cluster (http://hpc.nih.gov).

Received March 9, 2021; revised March 19, 2021; accepted April 7, 2021; published first May 25, 2021.

**REFERENCES**

Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Nonmalignant Clonal Hematopoiesis

Laura W. Dillon, Jack Ghannam, Chidera Nosiri, et al.


Updated version: Access the most recent version of this article at: doi: 10.1158/2643-3230.BCD-21-0046

Supplementary Material: Access the most recent supplemental material at: http://bloodcancerdiscov.aacrjournals.org/content/suppl/2021/04/09/2643-3230.BCD-21-0046.DC1

E-mail alerts: Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions: To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions: To request permission to re-use all or part of this article, use this link http://bloodcancerdiscov.aacrjournals.org/content/2/4/319. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.